FIELD: medicine.
SUBSTANCE: invention concerns medicine, namely to haematology, cardiology and endocrinology, and covers normalising the level of inhibitor of plasminogen activator in arterial hypertension (AH) with impaired glucose tolerance. It is ensured by complex treatment that involves graduated physical activities, as well as introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril 10 mg once a day in the morning.
EFFECT: invention provides normalising the level of inhibitor of plasminogen activator that resulted from 1,5-month therapeutic course; than in turn allows reducing risk of thrombotic complications in the given group of patients.
1 ex, 1 tbl
